Medical Weight Management in Singapore

Most people who seek help with their weight have already tried to lose it.

They may have eaten less, exercised more, followed diets, tracked calories, joined gyms or successfully lost weight several times — only to regain it.

Medical weight management starts from a different question. Instead of simply asking “How do we make the number on the scale go down?”, a doctor looks at why weight has been difficult to manage, whether it is affecting health, what has already been tried, and which treatments are medically appropriate.

This matters increasingly in Singapore. The most recent national population health survey found that the proportion of residents with obesity, defined as BMI ≥30 kg/m², increased from 10.5% in 2019–2020 to 12.7% in 2023–2024. The proportion with BMI ≥27.5 kg/m² — a level associated with increased chronic-disease risk in Asian populations — was 22.8%.

A medical weight-management programme may include:

• Assessment of weight history and health risks

• Blood pressure and waist measurement

• Selected blood tests where clinically appropriate

• Review of medications that may affect weight

• Nutrition and physical-activity planning

• Screening for obesity-related conditions

• Prescription medication when indicated

• Monitoring of side effects and health markers

• Muscle-preservation strategies

• A long-term maintenance plan

Medication may be part of treatment, but medical weight management is not simply the prescription of a weight-loss injection. The most important part is often what happens before and after the prescription.

Medical Weight Management in Singapore: The Key Facts

What Does “Medical Weight Management” Mean?

Medical weight management is the clinical assessment and treatment of excess weight and its health consequences. That is different from treating body weight purely as a cosmetic measurement.

The World Health Organization now describes obesity as a chronic, complex disease, and its 2025 guidance places GLP-1-based medicines within comprehensive, potentially long-term obesity care rather than as stand-alone weight-loss products.

A medical programme may therefore look at whether weight is contributing to:

• Type 2 diabetes or prediabetes

• High blood pressure

• High cholesterol or triglycerides

• Fatty liver disease

• Obstructive sleep apnoea

• Joint pain or reduced mobility

• Cardiovascular disease

• Reflux

• Polycystic ovary syndrome

• Reduced physical function

Success is not defined only by the smallest number achieved on the scale. For one patient, success might mean losing 15 kg. For another, it may mean losing 7 kg while normalising blood pressure, improving HbA1c and being able to climb stairs without knee pain.

Why Is Weight Sometimes So Difficult to Lose?

Body weight is influenced by much more than willpower. Food intake and physical activity matter, but so do:

• Genetics

• Age

• Sleep

• Appetite regulation

• Muscle mass

• Medications

• Work schedules

• Pregnancy-related weight changes

• Menopause

• Medical conditions

• Food environment

• Psychological and behavioural factors

Weight loss itself can also make further loss harder. As body weight falls, energy requirements decrease. Appetite may increase, and biological mechanisms favouring weight regain can persist after the active weight-loss period.

That does not mean the metabolism has been “damaged”. It means the body adapts to weight loss — which is one reason maintaining weight loss can be harder than achieving it.

Medical Factors That May Contribute to Weight Gain

Some patients have identifiable factors that deserve attention before simply prescribing a diet or medication. These may include:

• Medicines associated with weight gain, including some corticosteroids, psychiatric medicines, insulin and certain diabetes treatments

• Hypothyroidism

• Obstructive sleep apnoea

• Polycystic ovary syndrome

• Reduced mobility

• Poor or fragmented sleep

• Depression, anxiety or disordered eating

• Shift work and irregular eating patterns

National health guidance in Singapore similarly notes that several medicines — including steroids, insulin, some antidepressants, antipsychotics, beta blockers and sulfonylureas — can contribute to weight gain.

These factors do not explain every case of obesity, and most people do not have a single hidden hormonal disorder causing their weight. The purpose of medical assessment is to identify relevant contributors rather than assuming they are present.

What Happens at the First Weight-Management Consultation?

The first consultation should establish much more than height and weight. A doctor will usually ask about several areas.

1. Your weight history

This may include:

• When weight began to increase

• Previous highest and lowest adult weights

• Pregnancy-related changes

• Weight changes after starting medicines

• Previous diets or programmes

• Previous weight-loss medication

• How much weight was lost

• What happened when treatment stopped

Repeated regain is useful information. It may show that achieving weight loss is possible but that the maintenance strategy has been insufficient.

2. Your medical history

Particular attention may be given to:

• Diabetes or prediabetes

• Hypertension

• High cholesterol

• Heart disease

• Kidney disease

• Liver disease

• Gallbladder disease

• Previous pancreatitis

• Thyroid disorders

• Sleep apnoea

• Reflux or significant gastrointestinal symptoms

• Mental-health history

• Previous eating disorders

For women, pregnancy plans and menstrual history may also affect treatment decisions.

3. Your medication and supplement list

Bring a list — or photographs — of everything you take. This includes prescription medicines, over-the-counter medicines, supplements, traditional medicines and any weight-loss products purchased online.

This matters both for identifying medicines that may contribute to weight gain and for checking whether a proposed treatment is suitable.

Prescription weight-management medicines should be supplied through regulated healthcare channels. Prescription-only medicines require medical supervision and must be prescribed by a doctor.

4. Your eating pattern

A useful assessment is not necessarily a forensic calorie count. The doctor may ask about:

• Meal timing

• Skipped meals

• Portion sizes

• Snacking

• Sugary drinks

• Alcohol

• Takeaway and hawker meals

• Late-night eating

• Stress-related eating

• Hunger between meals

• How full you feel after eating

The aim is to identify a few changes that are realistic enough to continue.

5. Sleep and physical activity

Sleep is particularly relevant when there is loud snoring, witnessed pauses in breathing, morning headaches, poor-quality sleep or significant daytime sleepiness. These symptoms may suggest obstructive sleep apnoea, which is strongly associated with obesity and hypertension.

Activity assessment should include both deliberate exercise and everyday movement.

What Measurements Are Useful?

A medical assessment commonly includes weight, height, BMI, waist circumference and blood pressure.

BMI remains useful as a screening measurement, but it does not describe the entire clinical picture. National guidance notes its limitations in groups such as very muscular adults and people with sarcopenia. Waist measurement adds information about central adiposity and metabolic risk.

NICE's updated 2025 obesity guideline similarly recommends using waist circumference and waist-to-height ratio alongside BMI in many adults rather than relying on BMI alone.

BMI in Singapore: Why You May See Different Cut-Offs

This can be confusing, because health-risk thresholds and medication indications are not the same thing.

Singapore population-health data recognise that Asian adults can develop metabolic disease at lower BMI values, and BMI ≥27.5 kg/m² is tracked as a higher-risk category for chronic disease. Prescription medicines, however, have their own registered indications.

For example, the current Singapore indication for tirzepatide for adult weight management is:

• BMI ≥30 kg/m², or

• BMI ≥27 to <30 kg/m² with at least one weight-related condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes.

The semaglutide 2.4 mg weight-management product carries corresponding adult criteria of BMI ≥30 kg/m², or ≥27 kg/m² with a relevant weight-related comorbidity.

This is why a person may have increased metabolic risk at a BMI below the threshold at which a particular medicine is licensed for weight management.

Do You Need Blood Tests Before Starting?

Not everyone needs the same panel of tests. Testing should be based on the patient's history, examination, symptoms, risk factors and the treatment being considered. Commonly useful assessments may include:

Thyroid testing is not proof that obesity is caused by the thyroid, and it does not need to be performed solely to “justify” weight-management treatment. Similarly, abnormal liver tests may suggest fatty liver disease, but liver blood tests alone cannot diagnose every case.

Other investigations may be appropriate when symptoms suggest conditions such as sleep apnoea or polycystic ovary syndrome. You can read more about health screening in Yishun.

What Is a Good First Weight-Loss Target?

Patients often arrive with a goal based on a previous body weight: “I want to get back to 60 kg.” That may eventually be reasonable, but it is not always the most useful first milestone.

A sustained reduction of around 5–10% of starting body weight can already produce meaningful improvements in metabolic health in many patients. NICE, for example, describes 5–10% weight reduction as a realistic initial target associated with important health benefits in people at elevated diabetes risk.

For somebody who weighs 90 kg, 5% is 4.5 kg and 10% is 9 kg.

That does not mean treatment must stop after 10%. Modern obesity medicines can produce substantially greater average weight reductions in appropriately selected patients. The point is that clinically meaningful improvement often starts before someone reaches an “ideal” weight.

What Should Be Tracked Besides Kilograms?

Weight is useful, but it should not be the only outcome. A programme may also follow:

A month in which weight barely moves but waist circumference, blood pressure or glucose improve is not necessarily a failed month.

Nutrition: What Does a Medical Programme Actually Recommend?

There is no single compulsory “weight-loss diet”. The best dietary plan is one that creates an appropriate energy deficit while remaining nutritionally adequate and realistic.

In Singapore, that usually means designing a strategy that works with hawker food, restaurant meals, family meals and work schedules rather than pretending these do not exist. Useful priorities commonly include:

• Sufficient protein

• Vegetables, fruit and other fibre-rich foods

• Attention to portion size

• Reducing caloric drinks where relevant

• Regular meal patterns where helpful

• Choosing foods that provide greater satiety

• Avoiding unnecessarily severe restriction

The doctor does not need to prescribe every meal. The medical role is to identify where eating patterns are affecting health, ensure weight loss remains safe, and refer to a dietitian when more specialised nutrition input is appropriate.

Why Protein and Resistance Exercise Matter

When substantial weight is lost, not all of the change is body fat. Some non-fat or “lean” mass is usually lost as well.

Importantly, lean mass on a body-composition scan is not the same thing as skeletal muscle. Lean mass includes water and other non-fat tissues, so statements such as “one-third of the weight you lose is muscle” can be misleading.

Nevertheless, preserving strength and muscle should be an active part of weight management. Useful strategies include adequate protein intake, resistance exercise, avoiding unnecessarily extreme calorie restriction, and monitoring strength and function.

Protein needs vary according to body size, age, exercise and kidney function, so very high-protein targets should not be prescribed indiscriminately. Resistance exercise at least twice weekly is a useful general goal for many adults.

Where Do Weight-Loss Injections Fit?

Medication is one treatment within the programme, not the entire programme.

Weight-management medicines currently available in Singapore include treatments that act through GLP-1 pathways, as well as tirzepatide, which acts on both GIP and GLP-1 receptors. Liraglutide, semaglutide and tirzepatide products are registered in Singapore, although individual products have different approved indications.

These medications can reduce appetite, increase satiety, reduce food intake, affect glucose regulation and slow gastric emptying to varying degrees.

World Health Organization guidance considers GLP-1-based therapy a possible long-term treatment for adults with obesity as part of comprehensive care involving diet, activity and healthcare support.

Who may be suitable for tirzepatide?

Tirzepatide was registered in Singapore for weight management in June 2025. The adult indication is for weight management — including weight loss and weight maintenance — alongside reduced calorie intake and increased physical activity in patients with BMI ≥30 kg/m², or BMI ≥27 to <30 kg/m² plus at least one weight-related comorbidity.

Relevant associated conditions may include hypertension, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes and type 2 diabetes.

Meeting a BMI threshold does not automatically mean treatment is appropriate. A doctor must still assess medical history, current medication, potential contraindications, treatment goals and possible risks.

Are weight-loss injections safe?

They are prescription medicines with well-characterised benefits and adverse effects, but they are not suitable for everyone. Common adverse effects include nausea, vomiting, diarrhoea, constipation, abdominal discomfort and reduced appetite. Some gastrointestinal symptoms are more noticeable during dose escalation.

Less common but clinically important problems can include gallbladder disease, pancreatitis, dehydration-related complications and severe gastrointestinal symptoms. Previous pancreatitis should be discussed carefully with the prescribing doctor, but it should not be described generically as an absolute contraindication to every GLP-1-based medicine.

Pregnancy or plans for pregnancy also materially affect treatment decisions. Specific contraindications vary between products, so suitability should be assessed using the medicine actually being prescribed rather than applying one blanket list to the entire drug class.

Why Follow-Up Matters

Follow-up is not simply an appointment to record another weight. During treatment, a doctor may need to review:

• Weight trajectory

• Waist circumference

• Appetite

• Food intake

• Gastrointestinal side effects

• Hydration

• Blood pressure

• Blood glucose

• Changes in other medication requirements

• Strength and activity

• Whether the current dose remains appropriate

Sometimes the correct decision is not to increase a dose. If appetite suppression is already strong, nutrition is inadequate or side effects are significant, escalating treatment simply to accelerate weight loss may be inappropriate.

Follow-up frequency should be individualised according to the medicine used, dose-escalation schedule, health conditions and treatment stability rather than applying one fixed timetable to every patient.

What If the Weight Stops Falling?

A plateau does not automatically mean treatment has failed. Before changing medication, it may be useful to review:

• Whether portion sizes have gradually increased

• Liquid calories

• Alcohol

• Snacking

• Sleep

• Physical activity

• Resistance exercise

• Constipation or fluid shifts

• Medication adherence

• Whether the original target remains appropriate

As body weight falls, energy needs also decrease, so the calorie deficit that initially produced weight loss becomes smaller. Some patients also reach a new stable weight despite continued treatment.

The aim is not to force indefinite weight loss. It is to establish a body weight and health profile that provides meaningful benefit and can be managed safely.

Maintenance Is Part of Treatment

Most people plan how to lose weight. Far fewer plan what happens after the loss. That matters because appetite regulation does not permanently reset simply because somebody reaches a target weight.

Randomised withdrawal trials demonstrate this clearly. In SURMOUNT-4, adults lost an average of 20.9% of their body weight during an initial 36 weeks of tirzepatide. During the following year, those who continued treatment lost a further 5.5%, whereas participants switched to placebo regained 14.0%. A similar pattern was observed after withdrawal of semaglutide in the STEP 1 extension.

This is why maintenance should be discussed before medication begins. Options may include continued treatment where appropriate, lifestyle maintenance, regular weight monitoring and an agreed plan for early weight regain.

Does Medical Weight Management Improve More Than Weight?

Potentially, yes. The purpose of treating obesity is ultimately to improve health rather than only appearance. Depending on the patient and treatment, improvements may occur in blood pressure, blood glucose, insulin resistance, triglycerides, sleep apnoea, mobility, joint symptoms and cardiovascular risk.

One of the strongest examples comes from the SELECT cardiovascular-outcomes trial. Among 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg reduced the combined incidence of cardiovascular death, non-fatal heart attack or non-fatal stroke from 8.0% to 6.5% compared with placebo.

This does not mean every person taking semaglutide receives the same heart benefit. SELECT studied a particular high-risk population with established cardiovascular disease. The broader lesson is that obesity treatment can have clinically important outcomes beyond kilograms. You can read more about whether weight-loss injections protect your heart.

A Newer Way of Thinking About Obesity

In 2025, an international Lancet Diabetes & Endocrinology Commission proposed distinguishing between clinical obesity and preclinical obesity. Under this proposed framework:

• Clinical obesity refers to excess adiposity that is already causing organ dysfunction or meaningful limitation of everyday activity.

• Preclinical obesity refers to excess adiposity without current organ dysfunction but with increased future health risk.

The Commission also argued that BMI alone should not always be treated as a complete diagnosis, and suggested confirming excess adiposity using measurements such as waist circumference or direct body-composition assessment.

This is an influential expert framework, but it is important to put it in context. It is not a replacement for the current registered medication indications in Singapore, or for existing local clinical and population-health thresholds. Its practical value is simpler: two people with the same BMI may have very different health risks and therefore require different treatment.

Who Should Be Assessed Before Trying to Lose Weight?

Medical advice is particularly important if you have:

• Type 1 diabetes

• Type 2 diabetes treated with insulin or a sulfonylurea

• Significant kidney disease

• Significant liver disease

• Heart disease

• Previous pancreatitis

• Gallbladder disease

• Current or previous eating disorders

• Pregnancy or breastfeeding

• Plans for pregnancy

• Unexplained weight loss

• Major gastrointestinal symptoms

Children and adolescents also require different assessment and prescribing criteria from adults.

What About CHAS and MediSave?

This is worth clarifying, because “medical weight management” does not automatically mean the entire programme or weight-loss medication is claimable.

As of 2026, obesity itself is not one of the 23 conditions listed under Singapore's Chronic Disease Management Programme. The list does, however, include conditions that commonly coexist with obesity, such as diabetes, hypertension and lipid disorders.

Eligible patients may therefore be able to use CHAS or MediSave for qualifying treatment of a covered chronic condition, depending on scheme rules and clinic accreditation.

Do not assume that a weight-loss consultation or prescription weight-management medication is automatically subsidised simply because you have CHAS or MediSave. Ask the clinic what applies to the particular consultation, tests, medication and chronic conditions being treated. A breakdown of the cost components is set out in what tirzepatide treatment costs in Singapore.

Medical Weight Management vs Simply Getting an Injection

The difference is not whether a clinic offers an injectable medicine. It is what happens around it. A proper medical programme should answer questions such as:

• Why is this treatment appropriate for this patient?

• What health problem are we trying to improve?

• Which baseline measurements matter?

• How will side effects be monitored?

• How do we preserve strength and nutrition?

• When should treatment be continued, changed or stopped?

• What is the plan after the active weight-loss phase?

Medication without these questions is only one piece of care.

Frequently Asked Questions

What is medical weight management?

It is the medical assessment and treatment of overweight or obesity and associated health risks. It may include lifestyle changes, treatment of contributing medical problems, prescription medication where appropriate and ongoing follow-up.

Do I need to have obesity to see a doctor about my weight?

No. Assessment can also be useful for people with overweight who have metabolic risk factors, unexplained weight changes or repeated difficulty maintaining weight loss. Medication eligibility is a separate question and depends on the specific medicine and approved indication.

Is BMI 27.5 considered obesity in Singapore?

There are several thresholds in use for different purposes. BMI ≥27.5 kg/m² is recognised as a higher-risk category for chronic disease among Asian adults, while the standard categorisation defines obesity at BMI ≥30 kg/m². Prescription weight-management medicines have their own registered BMI criteria.

Do I need blood tests before starting?

Not every patient needs the same tests. HbA1c, cholesterol, kidney function or liver tests may be appropriate depending on individual risk, while thyroid testing is usually guided by clinical history or symptoms.

How much weight should I aim to lose first?

A reduction of around 5–10% can already provide meaningful health benefits for many patients. Further loss can then be considered according to health goals, response and treatment.

Is medication necessary?

No. Some patients can achieve their health goals without medication. Others may benefit from medication because of their degree of obesity, associated conditions, previous treatment history or difficulty maintaining weight loss.

Who can use tirzepatide for weight management in Singapore?

The registered adult indication includes BMI ≥30 kg/m², or BMI ≥27 to <30 kg/m² together with at least one weight-related comorbidity, alongside reduced-calorie intake and increased physical activity. Suitability still requires individual medical assessment.

Do weight-loss injections replace diet and exercise?

No. They alter appetite and food intake, but healthy nutrition, physical activity and muscle preservation remain important. World Health Organization guidance similarly recommends GLP-1-based treatment as part of comprehensive obesity care rather than as a stand-alone intervention.

How quickly should I lose weight?

For many adults, approximately 0.5–1 kg per week is a commonly used general guide, but appropriate rates vary according to starting weight and treatment. This is covered in more detail in our guide to how fast you can safely lose weight.

Will I lose muscle?

Some lean tissue is normally lost during substantial weight reduction, but lean mass is not synonymous with skeletal muscle. Adequate nutrition and resistance training help protect muscle and physical function.

Will I regain weight if I stop medication?

Weight regain is common after withdrawal of effective obesity medicines. It does not happen identically to everyone, but a maintenance strategy should be discussed before stopping treatment.

Can I use CHAS or MediSave?

Weight management itself is not currently listed as a Chronic Disease Management Programme condition. Eligible treatment for associated conditions such as diabetes, hypertension or lipid disorders may qualify under relevant schemes. Check with the clinic regarding your individual bill.

How often do I need follow-up?

This depends on the treatment being used, dose changes, side effects and associated conditions. Reviews are generally more frequent during initiation and dose escalation and may become less frequent once treatment is stable.

What if I have tried many times before?

That history is useful. A medical assessment should look at what worked previously, why it stopped working and what made maintenance difficult, rather than simply asking you to repeat the same approach more aggressively.

The Bottom Line

Medical weight management is not simply “eat less, exercise more”. And it is not simply “take an injection”. It is the structured medical management of weight and the health problems associated with it.

A good programme asks why weight has been difficult to manage, whether it is affecting health, whether contributing medicines or conditions are present, which tests are actually needed, what a realistic health target is, whether prescription medication is appropriate, how nutrition and muscle will be protected, how progress and side effects will be monitored, and what happens when the target weight is reached.

The last question may be the most important. Losing weight is one phase of treatment. Keeping the health benefits is the longer one.

Medical Weight Management at Nee Soon Clinic

Nee Soon Clinic provides doctor-led weight-management assessment in Yishun for adults who would like help managing overweight, obesity and associated metabolic health risks. Depending on individual needs, assessment may include:

• Weight and BMI

• Waist circumference

• Blood pressure

• Weight and medication history

• Diabetes and cardiovascular-risk assessment

• Selected blood tests

• Nutrition and physical-activity review

• Assessment of suitability for prescription weight-management medication

• Side-effect monitoring

• Muscle-preservation advice

• Long-term maintenance planning

Prescription weight-management medication is not suitable for everyone. Eligibility, choice of treatment, dose escalation, expected outcomes and follow-up should be determined after a personal medical consultation.

You can read more about medical weight loss at our Yishun clinic.

References

• Singapore National Population Health Survey 2024 — obesity prevalence and higher-risk BMI data.

• World Health Organization. Guideline on GLP-1 therapies for the treatment of obesity in adults, 2025.

• National Institute for Health and Care Excellence. Overweight and obesity management, NG246, updated January 2026.

• Rubino F, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes & Endocrinology, 2025.

• Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: SURMOUNT-4. JAMA.

• Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension.

• Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes: the SELECT trial. New England Journal of Medicine.

• Singapore Chronic Disease Management Programme — list of covered chronic conditions, 2026.

Official references: https://mounjaro.lilly.com/ and https://www.wegovy.com/

Related reading

Tirzepatide weight loss in Singapore: how to maximise results

What happens when you stop tirzepatide

Weight-loss injection side effects and how to manage them

Tirzepatide for type 2 diabetes and prediabetes

Semaglutide, tirzepatide and liraglutide compared

Medical weight loss at our Yishun clinic

Disclaimer:

The information provided in this article is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. The content is not intended to be a comprehensive source of information and should not be relied upon as such. Reliance on any information provided in this article is solely at your own risk. The authors and the publisher do not endorse or recommend any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned in the article. Any reliance on the information in this article is solely at the reader's own risk.